Kannu Bansal, Bharat Rawlley, Vidit Majmundar, Robert Beale, Miloni Shah, Andrzej S Kosinski, Tanush Gupta, Fahad Gilani, Saif Anwaruddin, Sahil Khera, Sreekanth Vemulapalli, Sammy Elmariah, Dhaval Kolte
{"title":"Out-of-Hospital 30-Day Mortality After Mitral TEER: Insights From the STS/ACC TVT Registry.","authors":"Kannu Bansal, Bharat Rawlley, Vidit Majmundar, Robert Beale, Miloni Shah, Andrzej S Kosinski, Tanush Gupta, Fahad Gilani, Saif Anwaruddin, Sahil Khera, Sreekanth Vemulapalli, Sammy Elmariah, Dhaval Kolte","doi":"10.1016/j.jcin.2025.01.425","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Transcatheter edge-to-edge repair of mitral valve (mTEER) is increasingly being adopted, with improved outcomes. However, it remains crucial to evaluate short-term out-of-hospital mortality to elucidate areas for further improvement.</p><p><strong>Objectives: </strong>The authors sought to evaluate incidence and predictors of out-of-hospital 30-day mortality after mTEER.</p><p><strong>Methods: </strong>We used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to identify patients who underwent mTEER between January 2014 and April 2023. Primary and secondary outcomes were 30-day out-of-hospital all-cause and cardiovascular mortality, respectively. Logistic regression and survival analysis models were used to identify factors associated with these outcomes.</p><p><strong>Results: </strong>Of 61,139 patients who underwent mTEER, 1,813 (3.0%) died within 30 days of the procedure. Of these, 744 (41.0%) died out-of-hospital after discharge. Cardiovascular causes accounted for 63.4% of out-of-hospital mortality at 30 days. The median (Q1-Q3) time from discharge to 30-day out-of-hospital all-cause mortality was 11 (5-19) days. Older age, White race, non-Hispanic ethnicity, lower baseline hemoglobin, poor baseline health status, presentation as non-ST-segment elevation myocardial infarction, lower left ventricular ejection fraction, higher acuity presentation, in-hospital complications, ≥moderate residual mitral regurgitation, and lack of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge were independently associated with higher 30-day out-of-hospital all-cause and cardiovascular mortality.</p><p><strong>Conclusions: </strong>Although overall 30-day all-cause mortality after mTEER was low, 2 of 5 deaths occurred out-of-hospital after discharge. Multiple modifiable factors such as patient selection, guideline-directed medical therapy underutilization and procedural complications require optimization to mitigate out-of-hospital mortality after mTEER.</p>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":11.7000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Cardiovascular interventions","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jcin.2025.01.425","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Transcatheter edge-to-edge repair of mitral valve (mTEER) is increasingly being adopted, with improved outcomes. However, it remains crucial to evaluate short-term out-of-hospital mortality to elucidate areas for further improvement.
Objectives: The authors sought to evaluate incidence and predictors of out-of-hospital 30-day mortality after mTEER.
Methods: We used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to identify patients who underwent mTEER between January 2014 and April 2023. Primary and secondary outcomes were 30-day out-of-hospital all-cause and cardiovascular mortality, respectively. Logistic regression and survival analysis models were used to identify factors associated with these outcomes.
Results: Of 61,139 patients who underwent mTEER, 1,813 (3.0%) died within 30 days of the procedure. Of these, 744 (41.0%) died out-of-hospital after discharge. Cardiovascular causes accounted for 63.4% of out-of-hospital mortality at 30 days. The median (Q1-Q3) time from discharge to 30-day out-of-hospital all-cause mortality was 11 (5-19) days. Older age, White race, non-Hispanic ethnicity, lower baseline hemoglobin, poor baseline health status, presentation as non-ST-segment elevation myocardial infarction, lower left ventricular ejection fraction, higher acuity presentation, in-hospital complications, ≥moderate residual mitral regurgitation, and lack of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge were independently associated with higher 30-day out-of-hospital all-cause and cardiovascular mortality.
Conclusions: Although overall 30-day all-cause mortality after mTEER was low, 2 of 5 deaths occurred out-of-hospital after discharge. Multiple modifiable factors such as patient selection, guideline-directed medical therapy underutilization and procedural complications require optimization to mitigate out-of-hospital mortality after mTEER.
期刊介绍:
JACC: Cardiovascular Interventions is a specialist journal launched by the Journal of the American College of Cardiology (JACC). It covers the entire field of interventional cardiovascular medicine, including cardiac, peripheral, and cerebrovascular interventions. The journal publishes studies that will impact the practice of interventional cardiovascular medicine, including clinical trials, experimental studies, and in-depth discussions by respected experts. To enhance visual understanding, the journal is published both in print and electronically, utilizing the latest technologies.